Population-based mammography screening below age 50: balancing radiation-induced vs prevented breast cancer deaths

por de Gelder, R, Draisma, G, Heijnsdijk, E A M, de Koning, H J
Publicado 2011

Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: a model-based approach on screening intervals

por van Ravesteyn, N T, Heijnsdijk, E A M, Draisma, G, de Koning, H J
Publicado 2011

To be screened or not to be screened? Modeling the consequences of PSA screening for the individual

por Wever, E M, Hugosson, J, Heijnsdijk, E A M, Bangma, C H, Draisma, G, de Koning, H J
Publicado 2012

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer

por Heijnsdijk, E A M, der Kinderen, A, Wever, E M, Draisma, G, Roobol, M J, de Koning, H J
Publicado 2009

Treatment of local–regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors

por Wever, E M, Heijnsdijk, E A M, Draisma, G, Bangma, C H, Roobol, M J, Schröder, F H, de Koning, H J
Publicado 2013

The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening

por van Luijt, P. A., Heijnsdijk, E. A. M., Fracheboud, J., Overbeek, L. I. H., Broeders, M. J. M., Wesseling, J., den Heeten, G. J., de Koning, H. J.
Publicado 2016

Effects of cancer screening restart strategies after COVID-19 disruption

por Kregting, L., Kaljouw, S., de Jonge, L., Jansen, E.E.L., Peterse, E.F.P., Heijnsdijk, E.A.M., van Ravesteyn, N.T., Lansdorp-Vogelaar, I., de Kok, I.M.C.M.
Publicado 2020

Socio-economic inequality of utilization of cancer testing in Europe: A cross-sectional study

por Bozhar, H., McKee, M., Spadea, T., Veerus, P., Heinävaara, S., Anttila, A., Senore, C., Zielonke, N., de Kok, I.M.C.M., van Ravesteyn, N.T., Lansdorp-Vogelaar, I., de Koning, H.J., Heijnsdijk, E.A.M.
Publicado 2022